Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVRx, Inc. (NASDAQ: CVRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular diseases, and its filings offer detailed insight into the Barostim platform, financial performance and risk profile.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue trends, gross margin, operating expenses, cash and cash equivalents, long-term debt and stockholders’ equity, as well as narrative discussions of the business and risk factors. These filings also describe CVRx’s focus on Barostim for heart failure, regulatory approvals such as FDA approval and CE Mark, and the importance of reimbursement and coding decisions to the company’s operations.
Current reports on Form 8-K document material events, including the release of quarterly financial results and key corporate developments. For example, CVRx has filed 8-Ks to furnish earnings press releases and to disclose the appointment of a Chief Operating Officer, along with details about compensation arrangements. Such filings help investors track significant changes in management, financing and operating plans.
Through this page, users can also access information related to CVRx’s capital structure, including term loan agreements secured by substantially all of the company’s assets, as described in its public communications. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as revenue drivers, Barostim-related updates, reimbursement discussions and key risk disclosures. Real-time updates from EDGAR, along with AI explanations of 10-Ks, 10-Qs and 8-Ks, allow investors to follow how CVRx’s regulatory reporting reflects the evolution of its heart failure therapy business.
CVRx, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on June 1, 2026. Investors will elect three Class II directors (including CEO Kevin Hykes and new nominee Michael Dale) for terms through 2029 and ratify Grant Thornton as independent auditor for 2026.
The proxy details governance practices, director and executive pay, and stock ownership. CVRx remains an “emerging growth company” and expects to lose that status on December 31, 2026, which will increase future reporting requirements.
CVRx, Inc. reported preliminary first quarter 2026 results showing total revenue of $14.7–$14.8 million, up from $12.3 million a year earlier, which is about 20% growth. Gross margin is expected to improve to roughly 87% from 84%, while total operating expenses are projected at about $25 million versus $23.7 million.
As of March 31, 2026, CVRx had 257 U.S. active implanting centers and 56 U.S. sales territories, and held approximately $72.3 million in cash and cash equivalents. The company highlights improved reimbursement after Category I CPT codes took effect, with 30‑day Medicare Advantage prior authorization approval rates rising from 31% in 2024 to 44% in 2025 and 50% for the first two months of 2026.
CVRx also activated the first site in its BENEFIT‑HF randomized trial on March 31, 2026, with enrollment expected to begin in the second quarter. If successful, this study could expand the indicated patient population for Barostim by about three times.
CVRx, Inc. reported that Chief Medical Officer Philip B. Adamson received new equity awards and completed a small share sale tied to tax withholding. On February 27, 2026, he was granted stock options for 62,000 shares of common stock at an exercise price of $8.16 per share, expiring on February 26, 2036, along with 41,000 restricted stock units. The restricted stock units vest 25% on each annual anniversary of the grant date, and the options vest 25% on February 27, 2027 with the remainder vesting monthly thereafter. On March 2, 2026, he sold 1,262 shares of common stock at a weighted average price of about $7.90 per share in multiple trades between $7.90 and $8.00, a sale that was mandated by the award agreement to satisfy tax withholding obligations through a sell-to-cover transaction. Following these transactions, he directly held 61,578 common shares.
Morrison Gregory reported acquisition or exercise transactions in this Form 4 filing.
CVRx, Inc. reported that Chief Human Resources Officer Gregory Morrison received equity awards on March 2, 2026. He was granted 154,500 stock options and 34,000 shares of common stock at no cost. The common stock represents restricted stock units vesting 25% annually, while the options vest 25% on March 2, 2027 and monthly thereafter.
CVRx, Inc. filed an initial statement of beneficial ownership for executive Gregory Morrison, who serves as Chief Human Resources Officer. This Form 3 establishes his status as an insider of the company and provides the baseline disclosure of his equity holdings for future reporting under securities rules.
CVRx, Inc. president and CEO Kevin Hykes reported both an equity award and a small tax-related sale. He received a grant of 238,000 stock options and 159,000 restricted shares, which vest over several years. To cover tax withholding from these awards, he sold 7,763 common shares at a weighted average price of $7.9027 per share in mandated sell-to-cover transactions. After these trades, he directly owned 284,237 common shares.
CVRx, Inc. Chief Marketing & Strategy Officer Paul Verrastro reported a mix of equity grants and a small sale. On February 27, 2026, he acquired 45,000 shares of common stock as restricted stock units and a 67,000-share stock option grant, both at no cost.
The restricted stock units vest 25% on each annual anniversary of the grant date, while the option vests 25% on February 27, 2027 and then monthly in equal installments. On March 2, 2026, he sold 1,284 shares of common stock at a weighted average price of $7.9021 per share, in transactions ranging from $7.90 to $7.98, to satisfy tax withholding obligations through a mandated sell-to-cover transaction. Following the sale, he directly held 60,551 shares of common stock and 67,000 stock options.
CVRx, Inc. chief financial officer Jared Oasheim reported a mix of equity grants and a small mandated share sale. He received a grant of 91,000 stock options at an exercise price of $0.0000 per share, vesting 25% on February 27, 2027 and then monthly thereafter. He was also granted 61,000 shares of common stock in the form of restricted stock units that vest 25% on each annual anniversary of the grant date. To cover tax withholding obligations from these awards, he sold 1,744 shares of common stock in an open-market sell-to-cover transaction on March 2, 2026 at a weighted-average price of $7.9022 per share, with individual sale prices ranging from $7.90 to $7.9831. After these transactions, he directly held 96,703 shares of common stock.
CVRx, Inc. Chief Revenue Officer John Robert Allen reported a mix of stock sales and awards. He sold 3,964 shares of common stock in an open-market transaction at a weighted average price of $7.9025 per share to cover tax withholding obligations from equity awards. He also received a grant of 35,000 restricted stock units and 52,000 stock options, both vesting over several years starting on February 27, 2027, increasing his long-term equity exposure to the company.
CVRx, Inc. chief operating officer Brent Binkowski reported equity awards on February 27, 2026. He received 23,000 stock options with an exercise price of $0.00 per share and a separate grant of 15,000 shares of common stock, both classified as awards rather than open-market purchases.
The 15,000-share common stock grant consists of restricted stock units that vest in four equal annual installments of 25% on each anniversary of the grant date. The 23,000-stock-option award vests as to 25% of the shares on February 27, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. After these transactions, Binkowski directly owned 31,600 shares of common stock, according to the filing.